ZOPTEC: Phase Iii Randomized Controlled Study Comparing Zoptarelin with Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (Nct01767155).
AuthID
P-00V-TB7
P-00V-TB7